Premium
Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light‐Chain Amyloidosis
Author(s) -
Meyers D. E.,
AduGyamfi B.,
Segura A. M.,
Buja L. M.,
Mallidi H. R.,
Frazier O. H.,
Rice L.
Publication year - 2013
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12391
Subject(s) - medicine , lenalidomide , bortezomib , amyloidosis , dexamethasone , immunoglobulin light chain , kidney , multiple myeloma , urology , immunology , antibody
We describe a patient who underwent a successful heart and kidney transplant for light‐chain amyloidosis. She had an excellent hematologic response to bortezomib/dexamethasone therapy. Follow‐up therapy with lenalidomide was started, and the patient quickly had a fatal allograft rejection of the heart and kidney. We present evidence to support the theory that lenalidomide, a known immunomodulator, may have stimulated the immune system and precipitated the fatal rejection episode.